Quick Answer
GT Biopharma, Inc. reported Net Income Loss of -$28.35 million for the year ending 2025.
- GT Biopharma, Inc. showed a decrease of -115.4% in Net Income Loss from 2024 to 2025.
- This data is from GT Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), GT Biopharma, Inc.'s Net Income Loss has declined by 846.7%.
- Historical annual values: Fiscal year 2025: -$28.35 million | Fiscal year 2024: -$13.16 million | Fiscal year 2023: -$7.60 million | Fiscal year 2022: -$20.88 million | Fiscal year 2021: -$58.01 million | Fiscal year 2020: -$28.30 million | Fiscal year 2019: -$38.65 million | Fiscal year 2018: -$259.19 million | Fiscal year 2017: -$144.17 million | Fiscal year 2016: $9.77 million | Fiscal year 2015: -$32.73 million | Fiscal year 2014: -$23.49 million | Fiscal year 2013: -$501.0 thousand | Fiscal year 2012: -$5.17 million | Fiscal year 2011: -$3.70 million | Fiscal year 2010: -$3.00 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: